

Cumulative Index 2005

Note: Page numbers of article titles are in **boldface** type.

A

- Acanthosis nigricans, familial, 251
- Adhesive restorations, cavity preparation design considerations for, 889–891
- Adhesive systems, self-etch, 895–897
total-etch, 892–895
- Adhesives, glass-ionomer, 897
- Advance health care directives, 405–406
- Aging, cognitive impairments and, 392–395
memory and, 391–392
- Air abrasion, for cavity preparation in caries, 874–876
- Alendronate, in osteoporosis, 470–471
- Allogenic bone grafts, for periodontal regeneration, 640–641
- Alloplasts, for periodontal regeneration, 642–643
- Alzheimer's Association's 10 Warning Signs, 400–402
- Alzheimer's disease, as cause of dementia, 398–403
criteria for diagnosing, 402
- Amalgam, dental, 320
- Amalgam preparations, class I, and extension for prevention, 816–817
- Amalgam tattoo, 197–198
- Amifostine, 317
- Amphotericin B, 62
- Anabolic agents, in osteoporosis, 473
- Analgesics, 420–421
- Anesthetics, local, 422–423
- Angiotensin-converting enzyme inhibitors, 414–415
- Ankyloglossia, 11
- Antibiotics, 419–420
in periodontal disease, 618–622
- Antibodies/infectious diseases, oral-based diagnostic tests for, 454
- Antidepressants, tricyclic, in trigeminal neuropathy, 352
- Antihypertensive agents, 416
- Anti-inflammatory agents, 421
in oral mucositis, 177–178
- Antimicrobials, in oral mucositis, 178–179
locally applied, 618–622
systemic, 622–623
- Antioxidants, in oral mucositis, 179–180
- Antiphospholipid syndrome, in lupus erythematosus, 137
- Antiseptics, periodontal disease and, 616–618
- Aphthous stomatitis, recurrent, **31–47**
allergic factors in, 37–38
characteristics of, 32, 33
clinical manifestations and pathogenesis of, 39–40
epidemiology of, 32–33
etiologic factors in, 34–39
hereditary and genetic factors in, 37
immunologic factors in, 38–39
management of, 40–42
medical disorders associated with, 36–37
microbial factors in, 35–36
nutritional factors in, 39
psychologic stress and, 39
- Arestin, 621–622
- Argyrosis, focal, 197–198
- Arthritis, polyjoint, in elderly, 327
in temporomandibular joint, pharmacologic treatment of, 337–338, 339

Arthritis (*continued*)
 social and economic impact of,
 327–328

Arthrocentesis-based lavage, in
 osteoarthritis of temporomandibular
 joint, 335–336, 339

Aspergillosis, 57

Atherosclerosis, periodontal disease
 associated with, 535–537

Atraumatic restorative treatment, 820–821

Atridox, 620–621

Autofluorescence, enamel, 755–756

Autogenous bone grafts, for periodontal
 regeneration, 640

Autoimmune diseases, saliva and, 311–314

Azoles, 59

B

B cells, and periodontitis, 506

Bacterial cultures, in periodontal disease,
 679–680

Behçet's syndrome, 36, 255

Biofilm-associated bacteria, antimicrobial
 resistance and, 494
 bacterial antigens and virulence factors
 in, 495
 cell-cell communication in, 494
 extracellular proteolytic enzymes and,
 497
 fimbriae in, 496–497
 gene transfer in, 494
 heat shock proteins and, 495–496
 lipopolysaccharide, 495
 regulation of gene expression in, 494

Biomarkers, host response and
 inflammatory mediators as, 555–557

Biotin, 600

Biphosphates, in osteoporosis, 470–471, 475

Bisphosphonates, in periodontal disease,
 685–686

Blastomycosis, 58

Blepharospasm, 344

Bonding and curing, considerations for, for
 hidden and incipient caries, **889–904**

Bone allograft, demineralized freeze-dried,
 for periodontal regeneration,
 641–642

 freeze-dried, for periodontal
 regeneration, 641

Bone grafts, allogenic, in periodontal
 regeneration, 640–641
 autogenous, in periodontal
 regeneration, 640
 human mineralized, for periodontal
 regeneration, 642
 replacement, for periodontal
 regeneration, 640–642

Bone matrix, demineralized, Grafton, for
 periodontal regeneration, 642

Bone mineral density, hormone replacement
 therapy and, 468–469
 low femur, prevalence of, 464
 measurement of, using dual energy
 x-ray absorptiometry (DEXA),
 465–466
 reduced, 463

Bone morphogenetic proteins, for
 periodontal regeneration, 645

Bone-specific markers, of tissue destruction,
 for periodontal diagnosis, 557–558

Bruxism, 344–345

Bullous pemphigoid, juvenile, 248

Burning mouth symptoms, 354–356

Burning tongue, 354

Burs, self-limiting polymer, for removal of
 hidden caries, 880–883
 site-specific, for preparation for
 preventive resin restorations,
 876–883

C

Caffeine consumption, and osteoporosis,
 468

Calcitonin, in osteoporosis, 472

Calcium, in body, 602, 605
 intake in aging, 467
 supplemental, to prevent bone loss,
 469, 470

Calcium channel blockers, 415

Cancer, oral, 369
 anatomic sites of, 145
 clinical examination in, 148–149
 delay in diagnosis of, 149–150
 etiology of, and risk factors of,
 146–147
 genomics and, 154–155
 imaging in, 159
 immune system and, 147

- incidence of, 144
 - leukoplakia, and squamous cell carcinoma, **143–165**
 - molecular progression of, 153
 - monoclonal antibodies for
 - detection of, 158–159
 - nutrition and, 148
 - precancerous classification of, 153–154
 - saliva-based diagnostics for, 455
 - signs and symptoms of, 150–152
 - stage at diagnosis and survival of, 145–146
 - tobacco use and, 147–148
 - viruses in development of, 148
- Candida infections, oral, 50
 - diagnosis of, 55–56
- Candida lesions, group I, classification of, 50–54
 - lesions associated with, 53–54
- Candidiasis, erythematous, 51
 - host factors associated with, 54–55
 - hyperplastic, 52–53
 - leukoplakia, and erythroplasia, 156
 - pseudomembranous, 50–51
- Capsaicin cream, in osteoarthritis of temporomandibular joint, 334
- Carbamazepine, in trigeminal neuralgia, 350
- Carbohydrates, intake of, caries and, 705–706
 - role in nutrition, 596–597
- Carcinogenesis, oral, 152–153
- Cardiovascular disease(s), and
 - periodontitis, in elderly, 287
 - in lupus erythematosus, 136
 - periodontal disease associated with, 535–537
- Cardiovascular drugs, 414–416
- Care staff, long-term, 380–381
- Caregivers, informal, 379–380
- Caries, active, and arrested, discrimination of, 835
 - early detection of, quantitative laser fluorescence for, 765–766
 - alternative management strategies for, 303–304
 - and restorative considerations, in dry mouth, 319–322
 - as multifactorial disease, 849–850
 - association with diet, in preschool children, **725–737**
 - Black classification of, 716–717
 - carbohydrate intake and, 705–706
 - cavity preparation design and, for adhesive restorations, 889–891
 - cavity preparation in, air abrasion for, 874–876
 - and restoration, 872–874
 - cavity size and, shrinkage and stress of restoration and, 898
 - clinical diagnosis of, uncertainties in, 850–851
 - commencing at contact area, 719
 - coronal, 294–295, 297, 302
 - defining, classifying, and placing in perspective, **701–723**
 - demineralization of tooth surface in, 702, 707–708, 709
 - detection of, and monitoring of, 912–914
 - DIAGNOdent for, 745–747, 802–803
 - DIFOTI diagnostic tool for, 803
 - digital imaging for, 799–800
 - and imaging process for, 744–745
 - methods of, 798–799
 - new technologies for, 868–869
 - quantitative light-induced fluorescence for, 800–802
 - radiographic examination for, 797–798
 - radiology for, 739–740
 - techniques of, 740, 743–744
 - traditional methods of, 754
 - visual and tactile examination for, 795–797
 - diagnosis of, detector dyes in, 854–856
 - new technology for, 833–835
 - earliest stages of, 701
 - early imaging and monitoring of, with near-infrared light, **771–793**
 - etiology of, 293–294
 - flow of saliva and, 309–310
 - fluoride exposure and, 706–707
 - gingival margin location, 858–859
 - hidden, and incipient, bonding and curing considerations for, **889–904**
 - dental hygiene management
 - options for, 804–811
 - management of, dental hygiene participation in, **795–813**
 - material for restoring, 900–901
 - nonsurgical treatment of, **905–921**
 - prevention/intervention/therapeutic plan for, 806–811

Caries (*continued*)

- detection of, quantitative laser fluorescence for, 766
 - diagnosis of, 867–868
 - radiography in, 833
 - removal with self-limiting polymer bur, 880–883
 - in cervical region, 720
 - in older adults, **293–308**, 431–433
 - incidence of, 295–296, 753, 833
 - incipient, and hidden, bonding and curing considerations for, **889–904**
 - material for restoring, 900–901
 - nonsurgical treatment of, **905–921**
 - contemporary treatment of, and conservative techniques in, **867–887**
 - instrumentation for, 871
 - magnification for, 872
 - restorative materials for, 871–872
- infection due to, treatment of, 905
- initiation and progression of, dietary factors in, 727–729
- into dentin, 713–715
- management of, 302–303
- future directions in, 304–305
- medical management of, New York University College of Dentistry, 915–916
- ozone treatment for, 917–918
 - patient communication for, 917
- near-infrared imaging and transillumination of, compared, 785–790
- noncavitated, monitoring of, emerging technologies for, 913–914
- occlusal, diagnosis of, 852–854
- detector dyes in, 855–856
- operative intervention thresholds for, 851–854
- operative management strategies in, conservative, **847–865**
 - for proximal only
 - restoration, 857–861
 - for proximal tunnel
 - restoration, 856–857
 - scientific rationale for, 849–851
 - minimally invasive, 847–849
- oral-based diagnostic tests for, 452–453
- patients at risk for, identification of, 804–806
- pit and fissure, incipient and hidden, clinical diagnosis of, 831–833
- sizes of, 718–719
 - prevalence of, 294–295
 - in nursing home elderly, 295, 296
 - prevention of, 299–302
 - process of, 726–727
 - quantitative light fluorescence for, **753–770**
 - understanding of, 804
 - proximal, management of, 852
 - re-restoration cycle and, 851
 - recurrent, minimizing of, 829–830
 - restoration in, design and preparation of, 720–721
 - risk to patient, and salivary flow, 911–912
 - assessment of, chart for, 910
 - classification of, 908–909
 - establishment of, 906–911
 - re-evaluation of, 912
 - root surface, 295, 297, 302–303
 - significance of, risk factors for, 298–299
 - to health and economics, 296–298
 - sites of, classification of, 717–718
 - transmission of, 726–727
 - treatment of, 870–871
 - early, evidence for and against, 835–838
 - risk analysis and, 835, 869–870
 - types of food products and, 729–730
 - untreated, in elderly, 367
 - “white spot” lesion and, 726, 754
- Cevimeline, 318, 319
- Chewing stick, 608
- Chickenpox, in children, 245–246
- Children, caries association with diet in, **725–737**
 - chickenpox in, 245–246
 - soft tissue lesions in, **241–258**
 - with HIV disease, orofacial disorders in, **259–271**
- Chlorhexidine, 585, 617
 - for caries control, 301
- Chromium, functions of, 604
- Cimetidine, 417
- Clonazepam, in burning mouth symptoms, 355
- Co-jet air abrasion system, 901
- Coenzyme Q₁₀, 607
- Cognitive changes, identification of, in dental office, 390–391
 - in elderly, recognition of, 395–396

- Cognitive function, aging, and ethical decisions, **389–410**
 - hints and suggestions for addressing, 406–408
 - loss of, with age, 391–392
- Cognitive impairment(s), and aging, 392–395
 - mild, 396–398
- Collagen, type 1, pyridinoline cross-linked carboxyterminal telopeptide of, 558–560
- Compomers, 321
- Composite, curing, stress relief in, 898–899
- Copper, sources of, 604
- Corticosteroid injections, in osteoarthritis of temporomandibular joint, 333, 339
- Crohn's disease, 36
 - and orofacial granulomatosis, 215–216
 - clinical findings in, 214–216
 - diagnostic tests in, 216
 - gene mutations in, 214
 - treatment and prognosis in, 216–217
- Cryotherapy, in oral mucositis, 180
- Cryptococcosis, 57
- Cyst(s), lateral periodontal, 234
 - pediatric oral, 254–255
- Cytomegalovirus, 24–25

D

- Decision-making capacity, assessment of, 404–405
- Dementia, 392–395
 - symptoms of, observed by dental team, 403
- Demineralized freeze-dried bone allograft, for periodontal regeneration, 641–642
- Dental and medical care, demand for, 449–452
 - for old-old, 451
 - for oldest-old, 450–451
 - for young-old, 451–452
- Dental care, versus medical care, subsidized, 366
- Dental caries. *See Caries.*
- Dental disability, adaptations to cope with, 436–438
- Dental disease, educational programs to prevent, 436–438
- Dental hygienist, in management of incipient and hidden caries, **795–813**
 - management options for, in hidden or incipient caries, 804–811
- Dental implants, osteoporosis and, 477–478
- Dental office, identification of cognitive changes in, 390–391
- Dental plaque. *See Plaque.*
- Dental use services, 366–367
- Dentin, and enamel, adhesion to,
 - contemporary principles of, 891–897
 - and sound enamel, optical properties of, in near-infrared light, 775–776
 - caries into, 713–715
- Dentists, medications prescribed by, 419–423
- Dentures, fibrous hyperplasia induced by, 235–236
- Dermatitis herpetiform, juvenile, 249–250
- Detector dyes, in diagnosis of caries, 854–856
- Diabetes mellitus, and periodontitis, in
 - elderly, 287–288
 - periodontitis in, treatment of, 546
 - risk of periodontitis in, 545
 - types of, 544
- DIAGNOdent device, 745–747, 802–803, 855–856, 881, 913–914
- Diet, caries association with, in preschool children, **725–737**
 - caries initiation and progression and, 727–729
- Dietary guidelines, oral health, for children,
 - 1 to 2 years old, 733–734
 - 2 to 5 years old, 734–735
 - birth to 1 year old, 732–733
 - for expectant mothers and preschool children, 735
 - in prenatal period, 731–732
- DIFOTI diagnostic tool, 747–749, 772, 803, 834, 914
- Digital imaging fiberoptic transillumination. *See DIFOTI diagnostic tool.*
- Digoxin, 416
- Diuretics, 415
- Drug-induced pigmentations, 198
- Drug monitoring, therapeutic, oral diagnostics for, 454–455

Drug reactions, lichenoid, 86
 Drugs. *See Medications.*
 Dry mouth, restorative treatment in, 319–322
 Durable power of attorney for health care, 405
 Dysesthesia, occlusal, 356–359
 explanations for, 357–358
 treatment of, 358–359
 Dysmorphophobia, 358
 Dysplasia, oral, and malignant transformation, 152
 Minnesota dentist's follow-up of, 151
 Dystonia, 344, 345

E

Ecchymosis, 190
 Echinocandins, 63
 Edentulousness, in elderly, 282–283
 Elderly, at risk for periodontitis and systemic diseases, **279–292**
 caries and, 431–433
 caring for, effective communication in, 383–388
 health care team and, 378–379
 interaction with health team members in, **377–388**
 cognitive changes in, recognition of, 395–396
 definition of, 279
 emergency and diagnostic services for, 431
 frail, oral health status of, 430–431
 gingivitis and periodontal disease in, 434
 issues of, underserved in United States, burdens of oral and medical health care, **363–376**
 medication use and prescribing considerations for, **411–427**
 oral diagnosis for, **445–461**
 oral hygiene and, 434–435
 oral implants for, 433–434
 prevention and treatment strategies for, 431–435
 prosthodontics for, 433
 restorative treatment for, 433
 Elderly Americans, and oral health status, 366–368
 rationale for targeting, 364–365

Enamel, and dentin, adhesion to, contemporary principles of, 891–897
 demineralized, optical property changes in, 776–778
 penetration of, by near-infrared light, 772, 773
 sound, and dentin, optical properties of, in near-infrared light, 775–776
 Enamel autofluorescence, 755–756
 Enamel fluorescence, 755–756
 Enamel lesion, early, 710–713, 714, 715
 Enamel matrix derivative(s), for periodontal regeneration, 646
 in periodontal disease, 684–685
 Endocrine agents, 418–419
 Endocrine disorders, pigmented lesions related to, 199–200
 Enzymatic assays, in periodontal disease, 680
 Epithelias, 187–188
 Epidermolysis bullosa, hereditary, 249
 Epstein-Barr virus, 25–26
 Epulis, congenital, 252
 Erythema migrans, 7–8
 Erythema multiforme, **67–76**
 classification of, 67–68
 clinical presentation of, 69–72
 diagnosis of, 72
 etiology of, 68
 features of, 67
 treatment of, 73–74
 Erythroleukoplakia, 348, 352, 363
 Erythroplasia, 155
 with ulceration, 155
 Estrogen-receptor modulators, selective, in osteoporosis, 471–472
 Ethical decisions, cognitive function, and aging, **389–410**
 hints and suggestions for addressing, 406–408
 Etidronate, in osteoporosis, 471
 Exercises, in osteoarthritis of temporomandibular joint, 333

F

Facial pain, of neurovascular origin, 349
 of vascular origin, 347–349

- related to chronic trigeminal neuropathy, 351–353
 - related to muscle pain, 345–347
 - related to postherpetic neuralgia, 353–354
 - related to trigeminal neuralgia, 349–351
 - Fiberoptic transillumination, 772
 - digital imaging. *See DIFOTI diagnostic tool.*
 - Fibroma, irritation, 223–224
 - peripheral ossifying, 231–232
 - traumatic, 223–224
 - Fibromatosis, gingival, 228–229
 - Fibromyalgia syndrome, 345–346
 - behavioral treatments in, 347
 - medications for, 346
 - Fibrous hyperplasia, denture-induced, 235–236
 - Fine-needle aspiration, 158
 - Fissured tongue, 10
 - Flaps, coronally positioned, for periodontal regeneration, 639–640
 - Florida Dental Care Study, 370
 - Fluorescence, enamel, 755–756
 - laser. *See Laser fluorescence.*
 - light, quantitative, for monitoring of caries process, **753–770**
 - light-induced quantitative, for detection of caries, 800–802
 - Fluoride, dietary, 595
 - exposure to, caries and, 706–707
 - functions of, 604, 753
 - in osteoporosis, 472–473
 - Fluoride dentifrice, to prevent caries, 299–300
 - Fluoride gels, to prevent caries, 300–301
 - Fluoride-releasing restorative materials, 321, 322
 - Fluoride rinses, to prevent caries, 300
 - Fluoride varnishes, to prevent caries, 301
 - Folate, 600
 - Fordyce granules, of labial and buccal mucosa, 4, 5
 - Forgetfulness, benign senescent, 396–398
 - FOTI technology, 834
 - Frailty, and long-term care recipients, 430
 - Freeze-dried bone allograft, for periodontal regeneration, 641
 - Fungal infections, oral, **49–65**
 - deep, 56–58
 - diagnosis of, 58–59
 - superficial, 49–50
 - treatment of, 59–63
-
- ## G
- Gastrointestinal agents, 417
 - Gene polymorphisms, 527
 - Geographic tongue, 7–8
 - Geotrichosis, 57–58
 - Geriatric populations. *See Elderly.*
 - Giant cell arteritis, 347–348
 - Gingiva, crevicular fluid sampling of,
 - diagnostic test based on, 563
 - recession of, 281–282, 523–524
 - retrocurved papilla of, 3
 - Gingival overgrowth, generalized, 232–234
 - Gingivitis, 518, 520
 - acute necrotizing ulcerative, in children, 241–242
 - bacteria associated with, 499
 - development of, plaque accumulation and, 501
 - in older adults, 434
 - necrotizing ulcerative, 500
 - Gingivostomatitis, primary herpetic, in children, 243, 244
 - Glass ionomers, conventional, 320
 - resin-modified, 320, 321
 - Glass-ionomers, adhesives for, 897
 - Glossitis, benign migratory, 7–8
 - Glossopyrosis, 354
 - Grafton demineralized bone matrix, for periodontal regeneration, 642
 - Granuloma, peripheral giant cell, 230–231
 - pyogenic, 229–230, 252
 - Granulomatosis, orofacial, causes of, 217
 - clinical findings in, 217–218
 - Crohn's disease and, 216–217
 - diagnostic tests in, 218
 - treatment and prognosis in, 219
 - Granulomatous diseases, immune-mediated granulomatous inflammation and, 205–206
 - in foreign body reactions, 204–205

Granulomatous (*continued*)
 of oral tissues, **203–221**
 common, 204

Growth factors/cytokines, for periodontal
 regeneration, 645–646

Guided cell repopulation/guided tissue
 regeneration, for periodontal
 regeneration, 644–645, 647–652

H

Hairy tongue, 9–10

Hand-foot-and-mouth disease, in children,
 245

Head and neck, cancer of, incidence of,
 143, 144
 TMN staging of, 146
 manifestations of lupus erythematosus
 in, 137–138

Health care, disparities in, history of,
 365–366
 poor access to, risk factors for, 363

Health care information, essential, 381–383

Health care proxies, 405

Health record, for older adults, basic
 elements of, 381–382
 decisional support and advanced
 directives of, 383
 functional assessment in, 382–383
 social history in, 382

Heart attack, periodontal disease and, 536

Heavy-metal pigmentation, 198

Heck's disease, in children, 247

Hemangioma(s), 195–196
 congenital, intraoral, 252

Hematologic disorders, in lupus
 erythematosus, 137

Hematoma, 190

Hemochromatosis, 199–200

Herbal supplements, periodontal disease
 prevention and, 607–608

Herpangina, in children, 244, 245

Herpes simplex infection(s), cytology
 smears in, 21
 differential diagnosis of, 20–21
 immunomorphologic tests in, 21
 primary, 16–17
 recurrent, 17–20
 serologic tests in, 21–22

virologic tests in, 21

Herpes simplex virus, 16

Herpes zoster, 22–24

Herpetic infections, oral (HSV 1-8), **15–29**

Histamine-2 receptor antagonists, 417

Histoplasmosis, 57

HIV disease, pediatric, classification system
 for, 260–261, 263, 264
 factors influencing, 259
 incidence of, 259–260
 oral lesions in, classification of,
 261–263, 265
 epidemiology of, 264–268
 treatment modalities for,
 268–269
 orofacial disorders in, **259–271**
 orofacial manifestations of, 261

Hormone replacement therapy, bone
 mineral density and, 468–469

Human herpes virus 6, 26

Human herpes virus 7, 26

Human herpes virus 8, 27

Human mineralized bone graft, for
 periodontal regeneration, 642

Hyaluronic acid injections, in osteoarthritis
 of temporomandibular joint, 334

Hydroxyapatite, 707

Hypertension, salivary hypofunction, 315

I

Ibandronate, in osteoporosis, 471

Imidazoles, 59–61

Immune system, periodontitis, in elderly,
 284

Immunoassays, in periodontal disease, 680

Incisive papilla cyst, 254–255

Infantile febrile mucocutaneous lymph node
 syndrome, acute, 250

Infection(s), bacterial, of pediatric soft
 tissue, 241
 fungal. *See Fungal infections.*
 in lupus erythematosus, 136–137
 initiating periodontal disease, 611–612
 related to caries, treatment of, 905

Inflammation, leading to tissue destruction,
 665–666

Informed consent, cognitive impairment and, 403–404

Informed decisions, ability to make, factors compromising, 404

Instruments, cavity preparation, effects on bonding, 899–900
for use in incipient caries, 871

Interdental cleaning, 581–582

Interleukin-1, in periodontal disease, 507

Interleukin 10, in periodontal disease, 508

Iodine, functions of, 603

Iron, importance of, 603
requirements for, 604

Irrigation, supragingival oral, 586

K

Kaposi's sarcoma, 196–197

Kawasaki disease, 250

L

Laser fluorescence, 745–747
quantitative, 834, 868, 914
Al-Khateeb study using, 759–760
components of system, 756–757
Connersville study using, 760–761
for detection of hidden caries, 765–766
for early detection of active caries, 765–766
history of, 756
images illustrating, 759
Indiana-Iowa validation study of, 764–765
investigations in, 757–758
Osaka study using, 762–764
software program for, 758
Tranaeus study using, 761–762

Laser fluorescence radiology, and transillumination, **739–752**

Laser therapy, in oral mucositis, 180

Lasers, for tooth preparation, 883–884

Lentigo, 188

Letters, consultative, for care of elderly patients, 385, 386, 387

Leukoedema, of labial and buccal mucosa, 3–4

Leukoplakia, 144, 149, 150

chemoprevention of, 160
cytology and brush biopsy of, 157–158
diagnosis and management of, 156–157
follow-up examination in, 160
oral cancer, and squamous cell carcinoma, **143–165**
proliferative verrucous, 155–156
stained with toluidine blue, 158, 159
treatment of, 160–161

Levothyroxine, 419

Lichen planus, as premalignant lesion, 84–86
cause and pathogenesis of, 78–79
clinical features of, 79–80
diagnosis of, and histopathologic features of, 81–83
epidemiology of, 77
erosive, 80, 81
oral, 148
plaquelike, 81
reactions in, diseases, drugs and materials implicated in, 85
reticular, 80
treatment of, 83–84

Lichenoid drug reactions, 86
lichen planus, and lichenoid mucositis, **77–89**

Lichenoid mucositis, lichen planus, and lichenoid drug reactions, **77–89**

Lidocaine patch, transdermal, in osteoarthritis of temporomandibular joint, 335

Life expectancy, 429–430

Lifespan developmental issues, in frail older adults, 448–449
in functionally dependent older adults, 449
in functionally independent older adults, 448
in oral diagnostics, 447–449

Light, near-infrared. See *Near-infrared light*.

Light fluorescence, quantitative, for monitoring of caries process, **753–770**

Light-induced fluorescence, quantitative, for detection of caries, 800–802

Linea alba buccalis, of labial and buccal mucosa, 5

Linear IgA disease, childhood, 248–249

Lipids, role in nutrition, 597

Lipoma, 234–235

- Lipopolysaccharide, from plaque biofilms, events triggered by, 554
- Lipopolysaccharide biofilm-associated bacteria, 495
- Lipoxins, in periodontal disease, 508
- Lip(s), commissural lip pits of, 1–2
ephelides of, 2
labial varices of, 2–3
- Living wills, 405, 406
- Long-term care patients, elderly, caring for, future trends in, 438–439
oral-health-related concerns in, **429–443**
quality of life in, oral health and, 437–438
frailty and, 430
- Long-term care staff, 380–381
- Low birth weight, preterm, and periodontal disease, 542–544
- Lupus erythematosus, acute cutaneous, 132
antiphospholipid syndrome in, 137
cardiovascular disease in, 136
chronic cutaneous, 129–132
clinical features of, 129
epidemiology of, 127
head and neck manifestations of, 137–138
hematologic disorders in, 137
infection in, 136–137
manifestations of, and impact on dental care, 130
mucocutaneous disease in, 129
treatment of, 134–135
mucosal lesions in, 132–133
neuropsychiatric manifestations of, 135
oral manifestations of, **127–141**
pathogenesis of, 127–129
renal disease in, 135
subacute cutaneous, 131
- Lymphangioma, 195, 252–253
- Lymphoid tissue, hyperplastic, 11–12
- M**
-
- Macrophages, periodontitis and, 505
- Magnesium, source of, 603
- Manganese, 604
- Measles, in children, 246
- Medicaid, 366
- Medical care, versus dental care, subsidized, 366
- Medications, frequently prescribed for older adults, 414–416
dental management considerations and, 415
oral effects of, for treatment of osteoporosis, 474
prescribed by dentists, 419–423
problematic or potentially inappropriate, for older adults, 414
problems related to, avoidance of, 423–424
factors contributing to, 413
polymedicine and, 412–413
salivary hypofunction and, 311
use of, and prescribing considerations for, in elderly, **411–427**
by older adults, 411–412
- Melanoacanthoma, 195
- Melanoma(s), oral mucosal, 193–195
- Melanoplakia, 187
- Melanosis, 187
- Melanotic macules, 188–189
- Melanotic neuroectodermal tumor of infancy, 253
- Memory, and aging, 391–392
- Microdentistry, concepts of, minimal intervention and, 827–829
- Minerals, importance of, 601–607
major, 602–603
trace, 603–604
ultratrace, 604
- Miswak, 608
- Molybdenum, 604
- Morsicatio buccarum, of labial and buccal mucosa, 5–6
- Mouth, dry, restorative treatment in, 319–322
floor of, lingual varicosities of, 12
- Mouthrinses, 582–585, 616–617
- Mucoccele(s), 191, 224–226
in children, 242–243
- Mucormycosis, 58
- Mucosa, labial and buccal, fordyce granules of, 4, 5
leukodema of, 3–4
linea alba buccalis of, 5

- morsicatio buccarum of, 5–6
 - traumatic ulcer of, 6–7
- oral, structure and appearance of, variations of, **1–14**
- Mucositis, oral, **167–184**
 - anti-inflammatory agents in, 177–178
 - antimicrobial agents in, 178–179
 - antioxidants in, 179–180
 - as complication of
 - chemotherapy, 168–169
 - clinical presentation of, 170–171
 - cryotherapy in, 180
 - diagnosis of, 172–173
 - growth factors in, 177
 - laser therapy in, 180
 - management of, 174–180
 - measurement of, 173–174
 - nutritional support in, 179
 - oral hygiene in, 174–176
 - pain control in, 176
 - pathogenesis of, 169–170
 - radiation therapy in, 167
 - topical coating agents in, 179
- Mumps, in children, 246
- Muscle pain, facial pain related to, 345–347
- Myalgia, localized, 345
- Myofascial pain, 345
 - behavioral treatments in, 347
 - medications for, 346
- N**

- Natural killer cells, periodontitis and, 505
- Near-infrared imaging, and transillumination, of caries, compared, 785–790
- Near-infrared light, early caries imaging and monitoring with, **771–793**
 - optical properties of dental hard tissue in, 774–775
 - optical properties of sound enamel and dentin in, 775–776
 - penetration of enamel by, 772, 773
- Neutropenia, congenital, 255
- Neutrophils, periodontitis and, 504–505
- Nevus(i), 192–193
- Niacin, 599
- Nonsteroidal anti-inflammatory drugs, 416–417, 422
- Nucleic acid probes, in periodontal disease, 680–681
- Nutrients, major, 595
 - recommended intake of, standards for, 596
- Nutrition, and oral cancer, 148
 - education and counseling in, 730–731
 - goals of, 725
 - general, healthy eating pyramid for, 728
 - periodontal disease and, **595–610**
 - role of, in periodontal disease, 604–607
- Nutritional supplements, periodontal disease prevention and, 607–608
- Nystatin, 62
- O**

- Older adults. See *Elderly*.
- Omeprazole, 418
- Optical coherence tomography, 773–774, 868–869
 - polarization sensitive, 778–784
- Optical transillumination, 772
- Oral cancer. See *Cancer, oral*.
- Oral cavity, bacterial population of, 703
 - testing of, 703
 - fluids of, for oral diagnostics, 446
 - maintenance of balance in, 702–703
- Oral diagnosis, and blood testing, compared, 445–447
 - approaches to, 445
 - benefits of, 445
 - for geriatric populations, **445–461**
- Oral diagnostics, future possibilities for, 455–457
 - lifespan developmental issues in, 447–449
 - specific applications of, 452–455
- Oral disease, and periodontal disease, diagnostic biomarkers of, **551–571**
- Oral fluid biomarkers, future directions for use of, 562–563
 - role of, in periodontal diagnosis, 561–562
- Oral health, osteoporosis and, 477–478
- Oral health professionals, in recognition of cognitive changes, 395–396
- Oral-health-related concerns, in caring for elderly long-term care patients, **429–443**
- Oral hygiene, elderly and, 434–435

- Oral implants, for older adults, 433–434
- Oral lesions, chronic and recurrent, in children, 248–251
 - in children, trauma as cause of, 247–248
- Oral motor disorders, facial pain in, 344–345
 - management of, 345
- Oral mucosa, structure and appearance of, variations of, **1–14**
- Orofacial disorders, in children with HIV disease, **259–271**
- Orofacial granulomatosis. See *Granulomatosis, orofacial*.
- Orofacial pain, and sensory disorders, in elderly, **343–362**
 - prevalence of, 343
 - types of, 343
- Osteoarthritis, polyjoint, and temporomandibular joint, in elderly, 336–337
 - in elderly, 327
- Osteocalcin, and periodontal disease, 560–561
- Osteoporosis, and oral health, 476–477
 - implications for dentistry, **463–484**
 - and periodontitis, in elderly, 288–289
 - dental implants and, 477–478
 - future study directions in, 478
 - in men, 474–476
 - incidence of, 463–464
 - morbidity and mortality associated with, 464–465
 - nature of, 465
 - pharmacotherapies for, 469–474
 - prevention of, 467–468
 - actions for dentists for, 478–480
 - risk factors for, 466
 - risk of, screening for, 466–467
 - treatment of, oral effects of, 474
- Ozone, for medical management of caries, 917–918

P

- Palate, hard and soft, tori and exostoses of, 13
- Pamidronate, in osteoporosis, 471
- Pantomography, 740
- Pantothenic acid, 599
- Papillary lesion, oral, 226–228
- Papillomavirus, human, 227–228
- Paraneoplastic pemphigus. See *Pemphigus, paraneoplastic*.
- Parathyroid hormone, in osteoporosis, 473
- Pemphigoid, bullous, juvenile, 248
 - mucous membrane, **91–106**
 - clinical presentation of, 93–94
 - diagnosis of, 95–100
 - epidemiology of, 92
 - management of, 100–103
 - pathophysiology of, 94–95, 96
- Pemphigus, **107–125**
 - paraneoplastic, clinical presentation of, 117–118
 - criteria for diagnosis of, 114–116
 - epidemiology of, 116
 - laboratory tests in, 118
 - pathophysiology of, 116–117
 - treatment of, 119
- Pemphigus vulgaris, clinical presentation of, 109–111
 - epidemiology of, 107–108
 - laboratory tests in, 111–114
 - pathophysiology of, 108–109
 - treatment of, 114
- Pep-Gen p-15, for periodontal regeneration, 646
- Peri-implant area, microbiology of, 664–665
- Peri-implantitis, **661–676**
 - and periodontitis, relationship of, 666–667
 - clinical appearance of, 669
 - definition of, 661, 667
 - histopathologic features of, 667–668
 - incidence of, 661–662
 - smoking and, 668
 - soft tissue around implants and, 662–663, 664
 - treatment of, 669–673
- Periochip, 618
- Periodontal abscess, 500
- Periodontal disease(s), 368
 - age, gender, and socioeconomic status predisposing to, 524–525
 - analysis of disease activity in, 682–683
 - and oral disease, diagnostic biomarkers of, **551–571**
 - antimicrobial approach to, 614–623, 686–687
 - assessment of status of, 587, 589
 - bacterial cultures in, 679–680
 - biosensors in, 681–682
 - dental plaque and, 492–493

- diagnosis of, 677–678
 - microbial factors for, 553–555
 - diagnostic criteria and measurement
 - methods in, 518–519
 - enzymatic assays in, 680
 - epidemiologic studies of, goals of, 518
 - epidemiology of, 520–524
 - and risk factors for, **517–532**
 - etiologic factors for, and risk factors
 - for, 524–527
 - etiology and pathogenesis of, **491–516**
 - focal infection hypothesis of, history
 - of, 533–535
 - future treatment and diagnostic
 - strategies for, **677–694**
 - genetic analysis in, 683
 - host modulatory approach to, 623–628
 - immunoassays in, 680
 - in atherosclerosis, cardiovascular
 - disease, and stroke, 525–537
 - in older adults, 434
 - in smokers, management of, 689–690
 - infection initiating, 611–612
 - matrix degeneration in, inhibition of,
 - 688–689
 - microbiologic testing in, 678–682
 - microorganisms in, 525–526
 - nucleic acid probes in, 680–681
 - nutrition and, **595–610**
 - oral-based diagnostic tests for,
 - 453–454
 - oral hygiene and, 526
 - polymerase chain reaction in, 681
 - predictors of, 552, 553
 - prevention of, **573–594**
 - risk assessment as aid in, 574–578
 - race/ethnicity and, 525
 - risk factors for, 612–614
 - risk reduction strategies, 615
 - smoking and, 526, 689–690
 - systemic effects of, **533–550**
 - treatment of, bisphosphonates in,
 - 685–686
 - diagnostic tests for, 631
 - enamel matrix derivatives in,
 - 684–685
 - nonsurgical approaches for,
 - 611–636**
 - periodontal regeneration
 - techniques for, **637–659**,
 - 683–684
 - photodynamic therapy in,
 - 687–688
 - regenerative, **637–659**, 683–684
 - treatment algorithm for,
 - 628–629
- Periodontal medicine, 280
- Periodontal Risk Calculator, 576
- Periodontitis, aggressive, 280
 - and peri-implantitis, relationship of,
 - 666–667
 - and systemic diseases, elderly at risk
 - for, **279–292**
 - and tooth loss, 663–664
 - anti-inflammatory cytokines and lipid
 - mediators in, 508
 - B cells and, 506
 - chronic, 280, 520–523
 - bacteria associated with,
 - 499–500
 - decrease in prevalence of, 282
 - diabetes mellitus and, 545–546
 - early-onset aggressive, 523
 - generalized aggressive, 500
 - genetic diseases associated with, 502
 - immune system and, in elderly, 284
 - localized aggressive, 500
 - macrophages and, 505
 - microbiologic etiology of, in elderly,
 - 284
 - natural killer cells and, 505
 - neutrophils and, 504–505
 - pathogenesis of, 612
 - host cells and molecules
 - implicated in, 503–504
 - prevalence of, and tooth loss in elderly,
 - 281–284
 - studies of, 282
 - prevention of, clinical considerations
 - for, 586–589
 - future strategies for, 589–590
 - proinflammatory and lipid mediators
 - in, 507–508
 - recurrence of, patient risk for, 575–576
 - risk assessment for, 613–614
 - risk modification of, 614
 - risk profile for, 289–290
 - self-perception, quality of life and, in
 - elderly, 285
 - severity of, factors defining, 283
 - smoking and, in elderly, 286–287
 - socioeconomic status and, 285–286
 - susceptibility to, 501–503
 - systemic diseases and, 287–289
 - T lymphocytes and, 500
- Periodontitis Index, 519
- Periodontium, age-related alterations in,
 - 283
 - biologic foundation of, 638–639
 - “compartmentalization” of, 638
 - health of, and disease, bacterial species
 - associated with, 497–499
 - regeneration of, clinical applications
 - of, 647–648
 - definitions in, 637–638
 - factors influencing, 646–647

- Periodontium (*continued*)
 guided tissue regeneration
 technique of, 644–645,
 647–652
 root surface conditioning for, 639
 surgical principles for, 647–652
 techniques for, 639–646
- Petechia, 190, 191
- Peutz-Jeghers syndrome, 200
- Pharyngitis, acute lymphonodular, in
 children, 244–245
- Phosphorus, sources of, 602–603
- Photodynamic therapy, in periodontal
 disease, 687–688
- Pigmentation, physiologic, 186–187
- Pigmented lesions, drug-induced, 198
 of benign, non-neoplastic hematologic
 or vascular origin, 189–191
 of oral cavity, **185–201**
 evaluation of, diagnostic
 approach in, 185–186
 of benign and malignant
 neoplastic melanocytic
 origin, 192–193
 of benign and malignant
 neoplastic vascular origin,
 195–197
 of benign melanocytic origin,
 186–187
 originating in salivary glands, 191
 related to endocrine disorders, 199
 related to exogenous deposits, 197–198
 related to systemic diseases, 199–200
- Pilocarpine, 318–319
- Pit and fissure sealant technique, 815
- Plaque, chemical control of, 582–586
 development of, as biofilm, 493–495
 mechanical control of, 579–582, 616
 periodontal disease and, 492–493
- Pneumonia, periodontal disease and,
 537–539
 prevention of, oral intervention trials
 for, 539–541
- Polyenes, 62
- Polymerase chain reaction, in periodontal
 disease, 681
- Polymerization shrinkage, 898
- Posttherapeutic neuralgia, facial pain related
 to, 353–354
- Potassium, functions of, 602
- Power of attorney, 405
- Pregnancy, adverse outcomes of, and
 periodontal disease, 542–544
- Preventive resin restoration(s), 826, 859–860
 and sealants, **815–823**
 outcomes of, 819–820
 pit and fissure sealants and, 816–822
 preparation for, site-specific burs for,
 876–883
 steps in use of, 818–819
 terminology associated with, 817
 “tunnel” restorations, 819
 types of, 818
 uses of, 818
- Prostaglandins, in periodontal disease,
 507–508
- Prosthodontics, for older adults, 433
- Protein-calorie malnutrition, 468
- Protein(s), need for, 605
 role in nutrition, 596
- Proton pump inhibitors, 417
- Psychotropic agents, 418
- Pulmonary disease, chronic obstructive,
 periodontal disease and, 541–542
- Pulp, preservation of vitality of, 831
- Purpura, 190
- Pyogenic granuloma, 229–230
- Pyridinoline cross-linked carboxyterminal
 telopeptide of type 1 collagen, 558–560
- Pyrimidines, 63
-
- Q**
-
- Quality of life and longevity, 371
-
- R**
-
- Radiation therapy, salivary hypofunction
 following, 314–315
- Radiographs, diagnostic accuracy of,
 740–741, 742
 for examination, frequency of,
 741–742
 quality of, and caries detection,
 technique factors in, 743–744
- Radiology, for detection of caries, 739–744
 laser fluorescence, and
 transillumination, **739–752**
- Raloxifene, in osteoporosis, 472

- Ranula, 191–192
- Recurrent aphthous stomatitis. See *Aphthous stomatitis, recurrent.*
- Regeneration techniques, periodontal, for treatment of periodontal disease, **637–659**
- Remineralization of tooth surface, 708–710, 711, 712
- Renal disease, in lupus erythematosus, 135
- Replacement bone grafts, in periodontal regeneration, 640–642
- Resin-based restoratives, polymerization considerations for, 897–899
- Resin restorations, preventive. See *Preventive resin restoration(s).*
- Resins, composite, 320, 321
polyacid-modified, 320
flowable composite, 876, 880
- Restoration(s), adhesive, cavity preparation design considerations for, 889–891
bonded, refurbishing of, 901
conservative proximal only, for primary molars, 861–862
resin, preventive. See *Preventive resin restoration(s).*
- Restorative materials, 320
direct, in reduced salivary flow, 321–322
fluoride-releasing, 321, 322
- Restorative treatment, atraumatic, 820–821
following treatment with sealants, 841, 842
for older adults, 433
in dry mouth, 319–322
treatment with sealants versus, 841, 842
- Rheumatic arthritis, and temporomandibular joint, in elderly, 337
- Riboflavin (Vitamin B₂), 599
- Riga-Fede disease, 253
- Risedronate, in osteoporosis, 471
- Root surface conditioning, for periodontal regeneration, 639
- Rubeola, in children, 246
- stimulation of, 704
testing of, 705
functions of, 309
roles of, in oral cavity, 704
- Salivary glands, diseases of, treatment of, 315
pigmented lesions originating in, 191
stimulation of, systemic, 318–319
with local or topical regimens, 318
- Salivary hypofunction, and xerostomia, diagnosis and treatment of, **309–326**
direct restorative materials in, 321–322
following radiation therapy, 314–315
in elderly, xerostomia and, 310, 312–313
in hypertension, 315
medications and, 311
prevention of, 315–317
treatment of, 316–318
- Sarcoidosis, as genetically heterogeneous disease, 210
clinical findings in, 210–212
diagnostic tests in, 212–213
treatment and prognosis in, 213–214
- Sealants, for use with resin restorations, 819–820, 821
to conserve tooth structure, 838–842
treatment with, followed by restoration, 841, 842
versus no treatment, 838–839
versus restoration, 839–841
- Sedatives, 421–422
- Selenium, functions of, 604
- Sensory disorders, and orofacial pain, in elderly, **343–362**
- Sialadenitis, acute viral, in children, 246
bacterial, in children, 242, 243
- Sjögren's syndrome, 311–314
- SMARTBUR, 881–883
- Smokers, periodontal disease in, 526, 689–690
- Smoking, and periodontitis, in elderly, 286–287
as risk factor for osteoporosis, 468
peri-implantitis and, 668
- Smoking cessation, pharmacotherapies approved for, 587, 588
- Socioeconomic disparities, health outcomes and, 369–370
- Sodium, functions of, 602
-
- S**
- Saliva, autoimmune diseases and, 311–314
flow of, and caries, 309–310

- Soft tissue lesions, pediatric, **241–258**
as manifestations of systemic disease, 255
- Soft tissue masses, oral, common benign, **223–240**
- Software program, for quantitative laser fluorescence, 758
- Squamous cell carcinoma, oral cancer, and leukoplakia, **143–165**
- Statins, in osteoporosis, 473
- Stevens-Johnson syndrome, 67
clinical presentation of, 69–72
diagnosis of, 73
etiology of, 68
treatment of, 73–74
- Stomatitis, recurrent aphthous. See *Aphthous stomatitis, recurrent.*
- Stomatopyrosis, 354–356
- Stroke, periodontal disease associated with, 535–537
- Subantimicrobial-dose doxycycline (Periostat), 624, 625–628
- Sulfonylureas, 418
- Sulfur, sources of, 603
- Supplements, herbal, periodontal disease prevention and, 607–608
nutritional, periodontal disease prevention and, 607–608
- Systemic diseases, and periodontal disease, 527, 534
periodontitis and, elderly at risk for, **279–292**
- Systemic lupus erythematosus. See *Lupus erythematosus.*
-
- T**
- T lymphocytes, periodontitis and, 506
- Tamoxifen, in osteoporosis, 471
- Telangiectasia, 190–191
- Temporal arteritis, 347, 348–349
- Temporomandibular joint, anatomy and physiology of, normal and age-related changes in, 328–330
and polyjoint osteoarthritis, in elderly, 336–337
derangement, osteoarthritis, and rheumatoid arthritis of, **327–342**
local disk dysfunction, in elderly, 330–331
localized osteoarthritis of, in elderly, 331–332
treatment of, 332–336
polyjoint arthritis in, pharmacologic treatment of, 337–338, 339
rheumatic arthritis and, in elderly, 337
wear-and-tear-related problems of, with aging, 329–330
- Thiamin (Vitamin B₁), 599
- Thiazides, 415
- Thrombocytopenic purpura, idiopathic, 255
- Thromboxanes, in periodontal disease, 507–508
- Thyroglossal duct cyst, 254
- Thyroid, lingual, 8–9
- Thyroid nodules, lingual, 8–9
- Tibolone, in osteoporosis, 472
- Tissue destruction, bone-specific markers of, for periodontal diagnosis, 557–558
- Tobacco use, oral cancer and, 147–148
- Toluidine blue, leukoplakia stained with, 158, 159
- Tomography, optical coherence, 868–869
- Tongue, crenations of, 11
fissured, 10
geographic, 7–8
hairy, 9–10
- Tooth, demineralization of surface of, in caries, 702, 707–708, 709
fracture of, decreasing incidence of, 830–831
molar, life cycle of, 825, 826
primary, conservative proximal only restorations of, 861–862
preparation of, lasers for, 883–884
structure of, conservation of, benefits of, 829–831
treatment decisions and conservation of, **825–845**
surface of, remineralization of, 708–710, 711, 712
- Tooth loss, impact of, in elderly, 282
periodontitis and, 663–664
reasons for, 283
- Tooth scaling, 616
- Toothbrushing, manual versus powered, 579–581

Toothpaste, 585, 617–618

Torticollis, 344

Toxic epidermal necrolysis, 67
 clinical presentation of, 72–72, 73
 diagnosis of, 73
 etiology of, 68
 treatment of, 73–74

Trace minerals, 603–604

Transillumination, 747–749
 and laser fluorescence radiology,
 739–752
 and near-infrared imaging, of caries,
 compared, 785–790
 digital imaging fiberoptic. See *DIFOTI*
 diagnostic tool.
 fiberoptic, 834, 868, 869
 optical, 772

Triamcinolone, in osteoarthritis of
 temporomandibular joint, 333

Triazoles, 61–62

Triclosan, in toothpaste, 617–618

Tricyclic antidepressants, in trigeminal
 neuropathy, 352

Trigeminal neuralgia, facial pain related to,
 349–351
 International Headache Society
 criteria for, 350

Trigeminal neuropathy, chronic, diagnosis
 of, 351–352
 clinical features of, 352
 treatment of, 352–353

Trihexyphenidyl, 345

Tuberculosis, clinical findings in, 207–208
 diagnostic tests in, 209
 susceptibility to, 206–207
 treatment and prognosis in, 209

Tumor necrosis factor α , in periodontal
 disease, 507

U

Ulcer, traumatic, of labial and buccal
 mucosa, 6–7

V

Varicella, 22
 in children, 245–246

Varicella zoster virus, 22

Varicosity, 189–190

Vascular inflammatory syndrome, chronic,
 347–349

Verruca vulgaris, 227, 228

Viral infections, in children, 243

Vitiligo, in children, 250

Viruses, in development of oral cancer, 148

Vitamin A, 597
 excess of, 605–606

Vitamin B, 599

Vitamin B₆, 600

Vitamin B₁₂ (cyanocobalamin), 600

Vitamin C (ascorbic acid), 601
 in periodontitis, 606–607

Vitamin D, 597–598
 intake in aging, 467
 periodontal attachment and, 607
 recommended intake of, 469

Vitamin E, 598

Vitamin K, 598–599

Vitamins, in nutrition, 597–601

W

Warfarin, 416, 417

Water, function of, 601

Waterlase, 883–884

“White spot” lesion, caries and, 726, 754

X

X-ray absorptiometry, dual energy
 (DEXA), for bone mineral density
 measurement, 465–466

Xenografts, for periodontal regeneration,
 643–644

Xerostomia, prevalence of, decreased
 salivary flow, in elderly, 310, 312–313
 restorative considerations in, 319–322
 salivary hypofunction and, diagnosis
 and treatment of, **309–326**

Xylitol, for caries prevention, 301–302

Y

Yttrium-scandium-gallium-garnet laser,
 883–884

Z

Zinc, importance of, 603

Zoledronate, in osteoporosis, 471